Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.74 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138888 | 1.00 | PIM1 (1.00) | PIM1KCNH2NTRK1NTRK3NTRK2 | |
| SCHEMBL102864 | 1.00 | PIM1 (1.00) | PIM1KCNH2NTRK1NTRK3NTRK2 | |
| SCHEMBL1053202 | 0.89 | PIM1 (0.80) | PIM1KCNH2NTRK1NTRK3NTRK2 | |
| SCHEMBL4692371 | 0.88 | PIM1 (0.79) | PIM1KCNH2NTRK1NTRK3NTRK2 | |
| SCHEMBL3041389 | 0.86 | PIM1 (0.78) | PIM1KCNH2FYN | |
| SCHEMBL3041385 | 0.86 | PIM1 (0.78) | PIM1KCNH2FYN | |
| SCHEMBL3044405 | 0.86 | PIM1 (0.78) | PIM1KCNH2FYN | |
| SCHEMBL2951802 | 0.86 | PIM1 (0.78) | PIM1KCNH2FYN | |
| SCHEMBL138855 | 0.85 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL3040037 | 0.85 | PIM1 (0.77) | PIM1KCNH2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885KCNH2 1556/4885NTRK1 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.